BioCentury
ARTICLE | Top Story

Crenezumab misses in AD Phase IIs

July 17, 2014 12:55 AM UTC

Crenezumab from the Genentech unit of Roche (SIX:ROG; OTCQX:RHHBY) missed the primary and secondary endpoints in two Phase II trials to treat Alzheimer's disease. Genentech said it is "premature" to discuss development plans for the humanized mAb against beta amyloid and that it plans to meet with FDA and EMA this year.

The placebo-controlled studies, ABBY and BLAZE, enrolled patients with mild to moderate AD. In both studies crenezumab was dosed either 300 mg subcutaneously every other week, which Roche called the low dose group, or 15 mg/kg intravenously every four weeks, which Roche called the high dose group. ...